MICHAEL TAYLOR to Disease Progression
This is a "connection" page, showing publications MICHAEL TAYLOR has written about Disease Progression.
Connection Strength
0.273
-
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011 Apr 10; 29(11):1408-14.
Score: 0.053
-
Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. Nat Commun. 2025 Mar 26; 16(1):2974.
Score: 0.037
-
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 2021 03 01; 39(7):807-821.
Score: 0.027
-
The AHR pathway represses TGF?-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma. Sci Rep. 2020 01 10; 10(1):148.
Score: 0.025
-
Evasion of Cell Senescence Leads to Medulloblastoma Progression. Cell Rep. 2016 Mar 29; 14(12):2925-37.
Score: 0.020
-
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016 04; 17(4):484-495.
Score: 0.020
-
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015 Mar 20; 33(9):1015-22.
Score: 0.018
-
MyoD is a tumor suppressor gene in medulloblastoma. Cancer Res. 2013 Nov 15; 73(22):6828-37.
Score: 0.017
-
Canonical TGF-? pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development. Brain Pathol. 2013 Mar; 23(2):178-91.
Score: 0.015
-
Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. Cancer Res. 2012 Feb 01; 72(3):636-44.
Score: 0.015
-
Neurosurgical management of extraaxial central nervous system infections in children. J Neurosurg Pediatr. 2011 May; 7(5):441-51.
Score: 0.014
-
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res. 2010 Jan 01; 70(1):181-91.
Score: 0.013